CN Bio Introduces Cross-species DILI Services to Enhance in Vitro to in Vivo Extrapolation During Preclinical Drug Development
- Extends capabilities of industry-leading PhysioMimix DILI assay for comparative studies between animal species and human
- Generates deeper insights into inter-species differences to de-risk development pipelines and minimize animal testing